research use only

Nerandomilast (BI 1015550) PDE4B Inhibitor

Name: Nerandomilast (BI 1015550)
Brand: Selleck Chemicals
SKU: E1382
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E1382

Nerandomilast (BI 1015550) is an orally active inhibitor of PDE4B with IC50 of 7.2 nM. It has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD).

Chemical Structure

Molecular Weight: 448.97

Jump to

Quality Control

Batch: E138201 DMSO]11 mg/mL]false]Ethanol]5 mg/mL]false]Water]Insoluble]false Purity: 99.54%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

99.54

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism Casein Kinase
Other PDE Inhibitors	Rolipram IBMX (3-Isobutyl-1-methylxanthine) Icariin Cilomilast Mardepodect (PF-2545920) Deltarasin PF-8380 Enpp-1-IN-1 Ibudilast BRL-50481

Solubility

In vitro
Batch:

DMSO : 11 mg/mL (24.5 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	448.97	Formula	C₂₀H₂₅ClN₆O₂S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1423719-30-5	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	PDE4B 7.2 nM
References	[1] https://patents.google.com/patent/US9150586B2/en?oq=US9150586 [2] https://pubmed.ncbi.nlm.nih.gov/35517783/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-20)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06238622	RECRUITING	Idiopathic Pulmonary Fibrosis; Progressive Pulmonary Fibrosis	Boehringer Ingelheim	2024-05-06	PHASE3
NCT06195072	RECRUITING	Interstitial Lung Disease Due to Systemic Disease; Scleroderma	Scleroderma Research Foundation, Inc.	2024-04-15	PHASE2
NCT06241560	COMPLETED	Idiopathic Pulmonary Fibrosis	Boehringer Ingelheim	2026-03-05	PHASE2
NCT05321082	COMPLETED	Lung Diseases, Interstitial	Boehringer Ingelheim	2022-11-16	PHASE3
NCT06393127	COMPLETED	Healthy	Boehringer Ingelheim	2024-06-04	PHASE1
NCT06408870	COMPLETED	Healthy	Boehringer Ingelheim	2024-06-06	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):